Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

67.48 +0.69 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,278,721
Open 65.99
Bid (Size) 62.20 (100)
Ask (Size) 68.50 (100)
Prev. Close 66.79
Today's Range 65.97 - 68.40
52wk Range 14.80 - 69.35
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool
News headline image
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+61.5%
+61.5%
1 Month
+11.4%
+11.4%
3 Month
+61.5%
+61.5%
6 Month
+69.3%
+69.3%
1 Year
+203.4%
+203.4%

More News

Read More
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
Via MarketMinute
Topics Earnings Economy
News headline image
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
Via MarketMinute
Topics Intellectual Property
What's going on in today's session ↗
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
News headline image
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
News headline image
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CG Oncology Announces New Board Member and Board Transition
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
Via The Motley Fool
News headline image
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Why Cg Oncology Stock Rocketed 7% Higher Today ↗
Via The Motley Fool

Frequently Asked Questions

Is CG Oncology, Inc. - Common stock publicly traded?
Yes, CG Oncology, Inc. - Common stock is publicly traded.
What exchange does CG Oncology, Inc. - Common stock trade on?
CG Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for CG Oncology, Inc. - Common stock?
The ticker symbol for CG Oncology, Inc. - Common stock is CGON on the Nasdaq Stock Market
What is the current price of CG Oncology, Inc. - Common stock?
The current price of CG Oncology, Inc. - Common stock is 67.48
When was CG Oncology, Inc. - Common stock last traded?
The last trade of CG Oncology, Inc. - Common stock was at 04/02/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.